TriSalus Life Sciences, Inc. (TLSI)

NASDAQHealth CareMedical - DevicesSnapshot 2026-10-23

$3.59-1.91%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge TriSalus Life Sciences, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	18.8M
EPS	—	-0.061
Annual ending 2026-12-31
Revenue	—	53.12M
EPS	—	-0.331
Annual ending 2027-12-31
Revenue	—	74.51M
EPS	—	-0.264

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Achieve FDA clearance for TriNav Advance	It is working to get FDA clearance for TriNav Advance.	Recovered	FDA clearance not achieved by end of 2026	FDA clearance achieved vs target by end of 2026 News confirms TriSalus received FDA clearance for TriNav Advance on 2026-09-22, with analysts raising price targets. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 2 quarters including a recent announcement of FDA clearance. Earlier in 2026-Q2, management referenced timing of FDA clearance impacting revenue guidance. The clearance achieved in 2026-09-22 expands the PEDD portfolio. The trajectory shows delivery of this regulatory milestone. Delivery assessment Oct 24, 2026
Operating income improves from -$8.41 million in 2026-Q1	A primary condition in TriSalus Life Sciences, Inc.'s published investment case. The stated target is Operating loss narrows vs -$8.41 million in 2026-Q1.	Intact	Operating loss worsens beyond -$8.41 million over next 4 quarters	Operating income: $-9.813M FY2026-Q2; GAAP. Published target: Operating loss narrows vs -$8.41 million in 2026-Q1. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026-9,813,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 4774a7da-7714-42ef-b783-bbd345256b1a. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Operating losses increased from $8.4 million in 2026-Q1 to $9.8 million in 2026-Q2 due to higher sales and marketing expenses, partially offset by gross margin improvement from 86.2% to 86.8%. The trajectory shows limited progress on operating income improvement given increased expenses. Delivery assessment Oct 24, 2026
Revenue grows to at least $54 million in 2026	A primary condition in TriSalus Life Sciences, Inc.'s published investment case. The stated target is >= $54 million.	Intact	Revenue falls below $54 million in FY26	Revenue: $11.407M FY2026-Q2; GAAP. Published target: >= $54 million. Target period is not explicitly aligned with this observation. Source published Aug 6, 202611,407,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 4774a7da-7714-42ef-b783-bbd345256b1a. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Revenue increased from $8.9 million in 2026-Q1 to $11.4 million in 2026-Q2. Management maintained full-year 2026 revenue guidance of $54 million to $57 million, reflecting ongoing commercial expansion. The trajectory shows delivering progress in expanding commercial operations and market penetration. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	3 / 3
2026-07-25	Unavailable	Unavailable	4 / 4
2026-07-26	Unavailable	Unavailable	4 / 4
2026-07-27	Unavailable	Unavailable	3 / 3
2026-07-28	Unavailable	Unavailable	4 / 4
2026-07-29	Unavailable	Unavailable	3 / 3
2026-07-30	Unavailable	Unavailable	3 / 3
2026-07-31	Unavailable	Unavailable	4 / 4
2026-08-01	Unavailable	Unavailable	3 / 3
2026-08-02	Unavailable	Unavailable	4 / 4
2026-08-03	Unavailable	Unavailable	4 / 4
2026-08-04	Unavailable	Unavailable	4 / 4
2026-08-05	Unavailable	Unavailable	4 / 4
2026-08-06	Unavailable	Unavailable	4 / 4
2026-08-08	Unavailable	Unavailable	3 / 3
2026-08-09	Unavailable	Unavailable	4 / 4
2026-08-10	Unavailable	Unavailable	4 / 4
2026-08-12	Unavailable	Unavailable	3 / 3
2026-08-13	Unavailable	Unavailable	4 / 4
2026-08-14	Unavailable	Unavailable	3 / 3
2026-08-15	Unavailable	Unavailable	3 / 3
2026-08-16	Unavailable	Unavailable	3 / 3
2026-08-17	Unavailable	Unavailable	3 / 3
2026-08-18	Unavailable	Unavailable	3 / 3
2026-08-19	Unavailable	Unavailable	3 / 3
2026-08-20	Unavailable	Unavailable	3 / 3
2026-08-21	Unavailable	Unavailable	3 / 3
2026-08-22	Unavailable	Unavailable	3 / 3
2026-08-23	Unavailable	Unavailable	3 / 3
2026-08-24	Unavailable	Unavailable	3 / 3
2026-08-25	Unavailable	Unavailable	3 / 3
2026-08-26	Unavailable	Unavailable	3 / 3
2026-08-27	Unavailable	Unavailable	3 / 3
2026-08-28	Unavailable	Unavailable	3 / 3
2026-08-29	Unavailable	Unavailable	3 / 3
2026-08-30	Unavailable	Unavailable	3 / 3
2026-08-31	Unavailable	Unavailable	3 / 3
2026-09-01	Unavailable	Unavailable	3 / 3
2026-09-02	Unavailable	Unavailable	3 / 3
2026-09-03	Unavailable	Unavailable	3 / 3
2026-09-04	Unavailable	Unavailable	3 / 3
2026-09-05	Unavailable	Unavailable	3 / 3
2026-09-06	Unavailable	Unavailable	3 / 3
2026-09-07	Unavailable	Unavailable	3 / 3
2026-09-08	Unavailable	Unavailable	3 / 3
2026-09-09	Unavailable	Unavailable	3 / 3
2026-09-10	Unavailable	Unavailable	3 / 3
2026-09-11	Unavailable	Unavailable	3 / 3
2026-09-12	Unavailable	Unavailable	3 / 3
2026-09-13	Unavailable	Unavailable	3 / 3
2026-09-14	Unavailable	Unavailable	3 / 3
2026-09-15	Unavailable	Unavailable	3 / 3
2026-09-16	Unavailable	Unavailable	3 / 3
2026-09-17	Unavailable	Unavailable	3 / 3
2026-09-18	Unavailable	Unavailable	3 / 3
2026-09-19	Unavailable	Unavailable	3 / 3
2026-09-20	Unavailable	Unavailable	3 / 3
2026-09-21	Unavailable	Unavailable	3 / 3
2026-09-22	Unavailable	Unavailable	3 / 3
2026-09-23	Unavailable	Unavailable	3 / 3
2026-09-24	Unavailable	Unavailable	3 / 3
2026-09-25	Unavailable	Unavailable	3 / 3
2026-09-26	Unavailable	Unavailable	3 / 3
2026-09-27	Unavailable	Unavailable	3 / 3
2026-09-28	Unavailable	Unavailable	3 / 3
2026-09-29	Unavailable	Unavailable	3 / 3
2026-09-30	Unavailable	Unavailable	3 / 3
2026-10-01	Unavailable	Unavailable	3 / 3
2026-10-02	Unavailable	Unavailable	3 / 3
2026-10-03	Unavailable	Unavailable	3 / 3
2026-10-04	Unavailable	Unavailable	3 / 3
2026-10-05	Unavailable	Unavailable	3 / 3
2026-10-06	Unavailable	Unavailable	3 / 3
2026-10-07	Unavailable	Unavailable	3 / 3
2026-10-08	Unavailable	Unavailable	3 / 3
2026-10-09	Unavailable	Unavailable	3 / 3
2026-10-10	Unavailable	Unavailable	3 / 3
2026-10-11	Unavailable	Unavailable	3 / 3
2026-10-12	Unavailable	Unavailable	3 / 3
2026-10-13	Unavailable	Unavailable	3 / 3
2026-10-14	Unavailable	Unavailable	3 / 3
2026-10-15	Unavailable	Unavailable	3 / 3
2026-10-16	Unavailable	Unavailable	3 / 3
2026-10-17	Unavailable	Unavailable	3 / 3
2026-10-18	Unavailable	Unavailable	3 / 3
2026-10-19	Unavailable	Unavailable	3 / 3
2026-10-20	Unavailable	Unavailable	3 / 3
2026-10-21	Unavailable	Unavailable	3 / 3
2026-10-22	Unavailable	Unavailable	3 / 3
2026-10-23	Unavailable	Unavailable	3 / 3
2026-10-24	Unavailable	Unavailable	3 / 3

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	5	0	0
2026-06-01	5	0	0
2026-07-01	5	0	0
2026-08-01	4	0	0
2026-09-01	5	0	0
2026-10-01	5	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 5 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Operating income improves from -$8.41 million in 2026-Q1Operating income: $-9.813M
Revenue grows to at least $54 million in 2026Revenue: $11.407M

Next proof point

Nov 10, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.3%Typical daily move · historical

Downside history

-66.4%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

TriSalus Life Sciences, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

TLSI is a small-cap, loss-making growth story with elevated risk, rather than an established durable compounder. Its long-term thesis is in a watch state: commercial progress is visible, but recent financial performance remains well below its industry cohort.

What's priced into TriSalus Life Sciences, Inc.

The evidence describes valuation as a justified premium to peers, with a durable premium as the main driver. The model has low confidence, and the negative expectations gap suggests expectations may be ahead of what current fundamentals support; no fragility gates have fired.

What the fundamentals likely do

Near term, revenue growth and the reaffirmed 2026 guidance support continued commercial expansion, while TriNav Advance received FDA clearance in September. However, operating losses widened in Q2 as sales and marketing costs rose, despite a modest improvement in gross margin. The August earnings miss and erratic recent surprises remain risks, even though the stated miss-risk tier is quiet.

What TriSalus Life Sciences, Inc. hinges on

The multi-year case hinges on whether wider market penetration and the expanded product portfolio can translate into stronger financial performance and better cost control. Near term, a guidance cut or further weakening in jobs data could weigh on the business outlook, while continued strength from sector bellwethers could support the healthcare backdrop.